The Anti—tumor Effects of an Anti—CD71 Chimeric Antibody in Vitro and Its Distribution in a Tumor Xenograft Model

Objective To investigate the anti-tumor effects in vitro and in vivo distribution of the human/murine chimeric antibody (D2C). Methods The CD71 positive target cells (K562, GEM and SMMC7721) and the effector cells, freshly isolated human PBMC, with the ratio of target cells to effector cells 1:50, were incubated in various dilutions of D2C antibody ( Ab) . Antibody dependent cytotoxicity (AD-CC) was tested by using an LDH-release assay. Instead of effector cells, complement was added to the target cells (GEM, SMMC-7721) with various dilutions of D2C Ab. A method of counting death cells was used in complement dependent cytotoxicity (CDC) assay. Tumor localization and distribution of the chimeric antibody (D2C) were observed by labeling the chimeric Ab with radioiodine(131I) and injecting it into nude mice (Balb/c nu/nu) transplanted with human hepatocellular carcinoma cells (SMMC-7721).Results A significant ADCC was observed with the increased concentration of the D2C Ab. Cytolysis of CD71-positive target cells by the D2C Ab was found in the presence of fresh rabbit complement. Labeled D2C administered by intraperitoneal as well as tumor regional injection, was visualized by SPECT. The distribution of D2C Ab in murine organs and tissues showed that non-specific binding was lower following tumor regional administration than when the antibody was administered by an intraperitoneal injection. The human/murine chimeric antibody (D2C) has in vitro anti-tumor effects and can exert its effects in specific tumor localization. Its distribution and local effects in vivo can be detected by radioimmunoimaging.Conclusion CD71 human/murine chimeric antibody showed marked killing of tumor cells in vitro, and specific recognition and high affinity binding to tumor tissue in vivo

改良Parks切口显微术与角膜缘梯形结膜瓣切口术治疗水平共同性斜视患者的疗效比较

目的探究改良Parks切口显微术与角膜缘梯形结膜瓣切口术对共同性斜视患者泪膜功能的影响。方法选取2019年2月至2021年3月虞城县人民医院收治的72例(113眼)水平共同性斜视患者作为研究对象,根据矫治方法不同将患者分为常规组(36例,56眼)、研究组(36例,57眼)。常规组予以角膜缘梯形结膜瓣切口术进行矫治,研究组予以改良Parks切口显微术进行矫治。比较两组矫治效果、手术指标、术前及术后各时间泪膜功能[泪膜破裂时间(BUT)、泪液分泌试验(SIT)、角膜荧光素染色评分(CFS)]、干眼症状问卷调查表评分及并发症情况。结果研究组总有效率(98.25%)高于常规组(85.71%)(P<0.05);研究组手术时间短于常规组,术中出血量低于常规组(P<0.05);术后1周两组BUT、SIT较术前缩短,研究组较常规组长,CFS评分、干眼症评分升高,研究组较常规组低(P<0.05);术后4周两组BUT、SIT、CFS评分、干眼症评分比较,差异无统计学意义(P>0.05);研究组并发症总发生率(3.51%)较常规组(16.01%)低(P<0.05)。结论同角膜缘梯形结膜瓣切口术相比,改良Parks切口显微术矫治水平共同性斜视效果显著,能优化手术情况,减轻泪膜功能损伤有助于缓解患者干眼症状,且能降低并发症发生风险。